HERZLIYA, Israel and CALGARY, AB, March 25, 2024 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP4) (OTCQB: INNPF) ('Innocan' or the 'Company'), a pioneer in the development of drug delivery technologies using CBD for the pharmaceutical and biotechnology industries, is pleased to announce the signing of an agreement with the Hebrew University, which facilitate  Innocan to initiate the Food and Drug Administration (FDA) approval process for its liposome CBD platform (LPT-CBD) in accordance with FDA's Chemistry Manufacturing Control (CDC) Guidelines..

以色列HERZLIYA和卡尔加里，AB，2024年3月25日/PRNewswire/--Innocan Pharma Corporation（CSE:INNO）（FSE:IP4）（OTCQB:INNPF）（“Innocan”或“公司”）是制药和生物技术行业使用CBD开发药物输送技术的先驱，很高兴宣布与希伯来大学签署协议，这有助于Innocan根据FDA的化学制造控制（CDC）指南启动其脂质体CBD平台（LPT-CBD）的食品和药物管理局（FDA）批准程序。。

To date, Innocan has focused on the development and characterization of LPT-CBD to achieve its long-term release and effectiveness. Innocan is now initiating the following essential development steps that are expected to move LPT-CBD to a pharmaceutical-grade product that must be qualified by the FDA for both the clinical and marketing phases:.

迄今为止，Innocan一直专注于LPT-CBD的开发和表征，以实现其长期发布和有效性。Innocan目前正在启动以下基本开发步骤，有望将LPT-CBD转变为药物级产品，该产品必须经过FDA的临床和营销阶段认证：。

The definition of the physical and chemical specifications of LPT-CBD as required from a pharmaceutical product.

根据药品的要求，定义LPT-CBD的物理和化学规格。

The expansion of LPT-CBD production from small laboratory quantities to large quantities in pharmaceutical grade.

LPT-CBD生产从实验室小批量扩展到制药级大批量。

Iris Bincovich Innocan Pharma's CEO stated: 'This is a major step in the development of LPT-CBD, moving it from a research laboratory-level drug to a pharmaceutical-grade product that must be qualified by the FDA for both the clinical and marketing phases.'

Iris Bincovich Innocan Pharma的首席执行官表示：“这是LPT-CBD开发的重要一步，将其从研究实验室级药物转变为必须经过FDA临床和营销阶段认证的药物级产品。”

About Innocan Pharma:

关于Innocan Pharma：

Innocan Pharma is a pharmaceutical technology enterprise operating primarily in two segments: Pharmaceuticals and Consumer Wellness. In the Pharmaceuticals division, Innocan is dedicated to developing cutting-edge drug delivery platforms infused with cannabinoid science to enhance patient quality of life.

Innocan Pharma是一家制药技术企业，主要经营两个领域：制药和消费者健康。在制药部门，Innocan致力于开发注入大麻素科学的尖端药物输送平台，以提高患者的生活质量。

This division is pioneering two drug delivery technologies: (i) LPT, a CBD-loaded liposome platform designed for precise dosing and controlled, prolonged CBD release into the bloodstream, currently in preclinical trials for epilepsy and pain management, and (ii) CLX, a CBD-loaded exosomes platform with potential regenerative and anti-inflammatory effects targeting the Central Nervous System (CNS).

该部门开创了两种药物输送技术：（i）LPT，一种载有CBD的脂质体平台，用于精确给药和控制，延长CBD释放到血流中，目前正在进行癫痫和疼痛管理的临床前试验，以及（ii）CLX，一种载有CBD的外泌体平台，具有针对中枢神经系统（CNS）的潜在再生和抗炎作用。

The Consumer Wellness division is focused on crafting innovative, high-performance self-care products to foster a healthier lifestyle. Under this division, Innocan has established a Joint Venture named BI Sky Global Ltd., specializing in advanced targeted online sales. For more information, visit (https://innocanpharma.com/). .

消费者健康部专注于打造创新、高性能的自我保健产品，以培养更健康的生活方式。在这个部门下，Innocan成立了一家名为BI Sky Global Ltd.的合资公司，专门从事先进的有针对性的在线销售。有关更多信息，请访问(https://innocanpharma.com/)。。

Contact Information:

联系方式：

For Innocan Pharma Corporation:

对于Innocan Pharma Corporation：

Iris Bincovich, CEO+1 5162104025+972-54-3012842+442037699377info@innocanpharma.com

Iris Bincovich，首席执行官+1 5162104025+972-54-3012842+442037699377info@innocanpharma.com

Disclaimer:

免责声明：

NEITHER THE CANADIAN SECURITIES EXCHANGE NOR ITS REGULATION SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

加拿大证券交易所及其监管服务提供商均未对本公告的充分性或准确性进行审查或承担责任。

Caution Regarding Forward-Looking Information

关于前瞻性信息的注意事项

This news release contains forward-looking information within the meaning of applicable securities laws, including but not limited to information regarding research and development, collaborations, potential FDA and other regulatory authority applications, anticipated approval timelines, new areas of medical research with CBD, future regulatory milestones, and potential treatment effects from research activities and/or the Company's products.

本新闻稿包含适用证券法含义内的前瞻性信息，包括但不限于有关研发、合作、潜在FDA和其他监管机构申请、预期批准时间表、CBD医学研究新领域、未来监管里程碑以及研究活动和/或公司产品潜在治疗效果的信息。

Such forward-looking information is subject to numerous risks and uncertainties, some of which are beyond Innocan's control. The forward-looking information is based on key expectations and assumptions made by Innocan, including the anticipated benefits of the products, regulatory satisfaction, and completion of production and distribution arrangements..

此类前瞻性信息面临众多风险和不确定性，其中一些风险和不确定性超出了Innocan的控制范围。前瞻性信息基于Innocan的关键期望和假设，包括产品的预期收益、监管满意度以及生产和分销安排的完成情况。。

Forward-looking information is subject to various risks and uncertainties that could cause actual results to differ materially from the anticipated results or expectations expressed in this news release. Key risks and uncertainties include global and local economic, market, and business conditions; governmental and regulatory requirements and actions; and relationships with suppliers, manufacturers, customers, business partners, and competitors.

前瞻性信息受到各种风险和不确定性的影响，这些风险和不确定性可能导致实际结果与本新闻稿中表达的预期结果或预期存在重大差异。主要风险和不确定性包括全球和当地的经济、市场和商业状况；政府和监管要求和行动；以及与供应商、制造商、客户、业务合作伙伴和竞争对手的关系。

There are also inherent risks in product distribution, including import/export matters and the failure to obtain necessary regulatory and other approvals in a timely manner. The anticipated timeline for market entry may change due to regulatory requirements or the need for additional time to conclude manufacturing and distribution arrangements.

产品分销也存在固有风险，包括进出口事项以及未能及时获得必要的监管和其他批准。由于监管要求或需要额外时间来完成制造和分销安排，市场进入的预期时间表可能会发生变化。

As a result, readers should not place undue reliance on the forward-looking information contained in this news release. Innocan does not undertake to update, correct, or revise any forward-looking information due to new information, future events, or otherwise, except as required by applicable law..

因此，读者不应过度依赖本新闻稿中包含的前瞻性信息。Innocan不承诺因新信息、未来事件或其他原因而更新、更正或修改任何前瞻性信息，除非适用法律要求。。

Readers are cautioned that undue reliance should not be placed on forward-looking information as actual results may vary materially from the forward-looking information. Innocan does not undertake to update, correct or revise any forward-looking information as a result of any new information, future events or otherwise, except as may be required by applicable law..

读者应注意，不应过度依赖前瞻性信息，因为实际结果可能与前瞻性信息有很大差异。Innocan不承诺因任何新信息、未来事件或其他原因而更新、更正或修改任何前瞻性信息，除非适用法律要求。。

Logo: https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

徽标：https://mma.prnewswire.com/media/2046271/3968398/Innocan_Pharma_Corporation_Logo.jpg

SOURCE Innocan Pharma Corporation

来源Innocan Pharma Corporation